Amikacin Sulfate: Mechanisms and Targeted Delivery in NTM Infections

Executive Summary: Amikacin Sulfate (CAS 149022-22-0) is a bactericidal aminoglycoside antibiotic effective against Mycobacterium avium and Staphylococcus aureus (Montes-Worboys et al., 2010). It operates by binding the bacterial 30S ribosomal subunit, halting protein synthesis and inducing cell death. At 64 mg/L, it sharply reduces CFUs in vitro, and at 1 mg/ml, it meets the MIC for M. avium (APExBIO product data). Targeted delivery using dendritic cells enhances local drug concentration in granulomas with minimal systemic exposure. Recent protocol innovations focus on maximizing intracellular uptake and reducing ototoxicity or nephrotoxicity (protocol review).

Biological Rationale

Non-tuberculous mycobacterial (NTM) infections, particularly those caused by Mycobacterium avium complex (MAC), present significant clinical challenges due to the formation of granulomas that sequester pathogens from systemic antibiotics (Montes-Worboys et al., 2010). Conventional therapies require high systemic doses, increasing the risk of adverse effects such as ototoxicity and nephrotoxicity. Targeted delivery strategies, leveraging the natural homing of dendritic cells (DCs) to granulomatous tissue, are under active investigation to overcome these barriers (Granuloma-Targeted Review). Unlike previous non-specific approaches, DC-mediated delivery can localize amikacin within granulomas, improving efficacy and safety.

Mechanism of Action of Amikacin Sulfate

Amikacin, the active agent in Amikacin Sulfate, is an aminoglycoside antibiotic that exerts bactericidal activity via irreversible binding to the 30S subunit of prokaryotic ribosomes. This binding impairs complex formation during translation, resulting in inhibition of protein synthesis and subsequent bacterial cell death (Montes-Worboys et al., 2010). Amikacin shows dose-dependent killing, with in vitro studies establishing a minimum inhibitory concentration (MIC) of 1 mg/ml against M. avium and potent activity against S. aureus at similar concentrations (APExBIO).

Importantly, amikacin can be internalized by mouse monocyte-macrophage RAW 264.7-derived DCs via passive diffusion, achieving intracellular levels above MIC without cytotoxic or pro-inflammatory responses at 25–100 mg/L (Montes-Worboys et al., 2010). This property underpins its suitability for targeted cellular delivery in NTM infection models.

Evidence & Benchmarks

• Amikacin Sulfate exhibits a MIC of 1 mg/ml against M. avium in vitro (APExBIO).
• At 64 mg/L, amikacin reduces CFU counts of both M. avium and S. aureus in vitro (APExBIO).
• Dendritic cells loaded with fluorescently-labeled amikacin (amikacin-FITC) deliver the drug into granulomas in mouse models without increasing monocyte chemoattractant protein-1 or CCR2, markers of inflammation (Montes-Worboys et al., 2010).
• The median lethal dose (LD50) for intravenous amikacin sulfate in mice is 181 mg/kg (APExBIO).
• Intracellular amikacin concentrations in DCs exceed the MIC threshold for M. avium without cytotoxicity at 25–100 mg/L (Montes-Worboys et al., 2010).
• DC-based delivery results in focal accumulation of amikacin in granulomatous tissue and minimal systemic presence (Montes-Worboys et al., 2010).

This article updates and extends the findings from "Targeted Amikacin Delivery into Granulomas for NTM Infections" by providing protocol-level detail on intracellular uptake and cytotoxicity thresholds.

Applications, Limits & Misconceptions

Therapeutic Applications: Amikacin Sulfate is a core antibiotic for non-tuberculous mycobacterial infections, especially those involving granulomatous sequestration (Montes-Worboys et al., 2010). Targeted drug delivery using DCs achieves high local concentrations within infected tissues, improving therapeutic index and potentially reducing the duration and toxicity of treatment (Amikacin Sulfate: Targeted Delivery and Protocol Innovations). This approach is under active investigation in preclinical mouse models.

Common Pitfalls or Misconceptions

• Systemic toxicity is unavoidable: Targeted delivery via DCs significantly reduces systemic exposure compared to traditional routes (Montes-Worboys et al., 2010).
• Amikacin cannot achieve effective intracellular concentrations: Studies confirm that dendritic cells can accumulate amikacin above the MIC without cytotoxicity (Montes-Worboys et al., 2010).
• All aminoglycosides have similar tissue penetration: Amikacin’s physicochemical properties and compatibility with DC-based delivery distinguish it from other aminoglycosides (Montes-Worboys et al., 2010).
• Long-term storage of solutions is feasible: Due to stability issues, it is recommended to avoid long-term storage of Amikacin Sulfate solutions (APExBIO).
• Granuloma targeting is clinically validated in humans: Current evidence is limited to murine models; translational studies are ongoing (Montes-Worboys et al., 2010).

Compared to "Amikacin Sulfate: Advanced Workflows for Intracellular Delivery", this article emphasizes in vivo evidence and key numerical thresholds for safety and efficacy.

Workflow Integration & Parameters

Protocol Parameters

• In vitro MIC testing: Prepare Amikacin Sulfate at 1 mg/ml for MIC assays against M. avium.
• Cellular loading: Incubate dendritic cells (e.g., RAW 264.7-derived) with 25–100 mg/L Amikacin Sulfate for 2–4 hours at 37°C to achieve intracellular concentrations above MIC without cytotoxicity.
• In vivo delivery: Inject amikacin-loaded dendritic cells intravenously into murine models with established granulomas; analyze tissue localization within 24 hours.
• Storage: Store Amikacin Sulfate powder at -20°C, protected from moisture and light. Avoid prolonged storage of prepared solutions.
• Shipping: Ship with blue ice for small molecules to maintain stability.

These guidelines are synthesized from peer-reviewed evidence and APExBIO product documentation. For troubleshooting of intracellular delivery workflows, see Amikacin Sulfate: Targeted Delivery and Protocol Innovations; this resource provides stepwise optimizations and troubleshooting for maximizing intracellular uptake.

Conclusion & Outlook

Amikacin Sulfate, as supplied by APExBIO, remains a critical research tool and therapeutic candidate for non-tuberculous mycobacterial infections. DC-mediated targeted delivery achieves high local antibiotic concentrations in granulomas with minimal systemic toxicity, as confirmed in murine models (Montes-Worboys et al., 2010). Future research will focus on optimizing delivery protocols and translating these findings into clinical practice. All outlook claims are based exclusively on cited evidence from published studies and product data.